الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 189 |  |  |
| | | from | 189 | | |
Abstract
Introduction: modulation of autophagy is a promising potential strategy enhancing cancer therapy, especially after development of new autophagy inhibitors. We planned to assess prospectively the role of autophagy in Myelodysplastic syndrome (MDS) and Myeloproliferative neoplasms (MPNs).
Study: Prospective case controlled ”single center” study was carried in the Internal medicine department, Minia University Hospital, Minia.
Subjects & Methods: A total of 70 subjects divided into two groups: group I: 35 newly diagnosed patients with MDS and MPNs and group II: 35 apparently normal individuals. Serum beclin-1 (S.BECN 1) and Serum autophagy protein 7(S. Atg7) were measured in both groups.
Results: By comparing S.BECN 1 and S. Atg7 in both groups, there was statistically significant elevation in their values in the patient group compared to the control group.
The housekeeping function of autophagy had been attracted a major attention over the last decade as it has a broad variety of roles in health and disease.
Detection of high level of S. BECN 1and S. Atg 7 in MDS and MPNs indicate that they can be autophagy dependent markers and it may be a therapeutic window for autophagy inhibition for cancer therapy and prevention.
The modulation of autophagy is a promising potential strategy to enhance cancer therapy, especially after the development of new autophagy inhibitors which is an attractive field of research.
However, many challenges remain as it needs more and more studies of larger sample size to validate and approve autophagy inhibitors in blood malignancy therapy protocols.
Autophagy, is a potentially modifiable factor through its induction or inhibition, so it has a crucial prognostic and therapeutic implications in the management of different blood malignancies.